clinical trial · NCT00649272
Fasting Study of Oxybutynin Chloride Extended-Release Tablets 15 mg and Ditropan XL® Tablets 15 mg
HealthyOxybutynin Chloride Extended-Release Tablets, 15 mgDitropan XL® Extended-release tablets, 15 mg
brief summary
The objective of this study was to investigate the bioequivalence of Oxybutynin Chloride Extended-Release Tablets, 15 mg (Mylan Pharmaceuticals Inc.) to Ditropan XL® Extended- Release Tablets, 15 mg (ALZA Corporation; Distributed and marketed by: Ortho-McNeil Pharmaceuticals Inc.) following a single, oral 15 mg dose (1 x 15 mg tablet) under fasting conditions.
started
Jan 1, 2006
primary completion
Jan 1, 2006
completion
Feb 1, 2006
last updated
Apr 24, 2024
official title
Single-Dose Fasting Bioequivalence Study of Oxybutynin Chloride Extended-Release Tablets (15 mg; Mylan)and Ditropan XL® Tablets (15 mg; ALZA) in Healthy Volunteers
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol